Mandate

CapMan Oy and 3i Group – sale of NeoPharma AB to Solvay Pharmaceuticals

May 10, 2005

Solvay Pharmaceuticals, the Belgium based pharmaceuticals firm, has agreed to acquire NeoPharma AB, the Sweden based pharmaceuticals firm involved in development of drugs for the treatment of Parkinson's disease, from 3i Group plc, the UK based private equity firm, and CapMan, the Finnish private equity firm, in a transaction, for approximately SEK 640m (EUR 71.26m).

Vinge acted for the sellers, being private investors as well as private equity funds including 3i and CapMan.
Anders Åberg, Malin Ohlin Åkermark (reponsible partners)
Maja Wettergren, Ola Sandersson (associates)

Related

Vinge advises Adelis Equity Partners on the establishment of a continuation fund

Vinge has advised Adelis Equity Partners on the establishment of a continuation fund to Adelis Equity Partners Fund II. The continuation fund is a so-called dual-asset vehicle which will invest in Presto and HVD Group (Hantverksdata) – both current portfolio companies of Adelis Equity Partners Fund II. The continuation fund, in which HarbourVest Partners will be the largest investor, will have EUR 430m in commitments and will invest alongside Adelis Equity Partners Fund III and the Adelis team.
February 21, 2024

Vinge advises Axcel and XPartners in connection with the acquisition of Wavecon

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of Wavecon AB (”Wavecon”).
February 14, 2024

Vinge advises Axcel and XPartners in connection with the acquisition of Projektstaben

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of Projektstaben i Sverige AB (”Projektstaben”).
February 14, 2024